immunotherapy

By investigating how gut bacteria influence immunotherapy responses in mice, researchers found a molecule involved in treatment resistance.

This year’s Breakthrough Prizes honor advances in CAR T cancer therapies, cystic fibrosis, and Parkinson’s disease.

Exosomes show encouraging results for treating melanoma, offering potential benefits for targeted drug delivery and immunotherapy.

Epigenetic therapies revive the immune cell offensive in immunotherapy resistant tumors.

Allogeneic T cells may serve as universal, ready-to-use therapeutic agents for large scale clinical applications.

With childhood peanut allergies on the rise, scientists itch to find ways to prevent deadly reactions to this ubiquitous food.

The dream of oncology is precise targeting to destroy cancer cells while avoiding harm to healthy tissues. Identifying the unique proteins of a tumor might finally help reach that goal.

Using tiny chambers that release signals from a patient’s own tumor, scientists trigger immune cells to mount a personalized attack against the cancer.

Researchers identified immune cell imposters that are responsible for immune evasion in pancreatic cancer.

The complex interplay between bacteria and the tumor microenvironment informs cancer immunotherapy strategies.